Navigation Links
Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

SummaryGBI Research, the leading business intelligence provider, has released its latest research, "Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market", which provides insights into global antibacterial market and market forecast until 2016. The report provides an in-depth analysis of the top seven therapeutic indications for which often antibacterials are prescribed which includes tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media. The report also examines the Global antibacterial treatment usage patterns for the covered indication. In addition, the report also includes insights into the antibacterial R&D pipeline.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the overall global antibacterial market for the seven indications tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media is valued at $11,070m in 2009. The market is expected to witness a growth at a CAGR of 1.5% for the forecast period and will reach $12,160m by 2016. Patent expiries of leading antibacterial, weak pipelines, increase in prevalence and prescription populations and easy availability of generic products are the main reason for growth in antibacterial market. The top pharmaceutical companies in antibacterial market companies – Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCareAG, Johnson & Johnson, Daiichi-Sankyo and Teva pharmaceuticals. Large amount of fragmentation in the market provides significant Scope for consolidation through mergers and acquisitions.

ScopeThe scope of this report includes -

- Data and analysis on the global antibacterial market.

- Annualized market data for the antibacterial market from 2001 to 2009, with forecasts to 2016.

- Market data on the therapeutic landscape which covers tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.

- Key drivers and restraints that have had a significant impact on the market and on each indication.

- The competitive landscape of the global anticonvulsant market which includes companies such as Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCare AG, Johnson & Johnson, Daiichi-Sankyo and Teva.

- Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global antibacterial market.

Reasons to buyThe report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

- Device a more tailored country strategy through the understanding of key drivers and barriers of the region's antibacterial market.

- Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

To order this report:Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
2. Reportlinker Adds Manufacturing of Solid Dosage Forms - 2011
3. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
4. Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013
5. Reportlinker Adds US Market for PACS, The
6. Reportlinker Adds Global Anti-counterfeit Markets in Food & Pharmaceutical Applications by Geography, Technology Trends and Forecasts (2010-2015)
7. Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015)
8. Reportlinker Adds Analytical Tool - Antibodies and Peptides in Oncology
9. Reportlinker Adds Analytical Tool - Cancer Therapeutic Antibodies
10. Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011
11. Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
Breaking Medicine News(10 mins):